International Scholarly Research Notices

International Scholarly Research Notices / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 526075 | 10 pages |

Identification of Unique miRNA Biomarkers in Colorectal Adenoma and Carcinoma Using Microarray: Evaluation of Their Putative Role in Disease Progression

Academic Editor: D. Arnoult
Received09 Jun 2013
Accepted07 Jul 2013
Published22 Apr 2014


MicroRNAs (miRNAs) are known to be dysregulated and play a key role in cancer progression. The present study aims to identify the miRNAs associated with colorectal adenoma and carcinoma to evaluate their role in tumor progression and metastasis using microarray. In silico analysis of miRNAs was performed on five different microarray data sets that represented the genes and miRNAs expressed in colorectal adenoma and carcinoma. We identified 10 different miRNAs that were common to both colorectal adenoma and carcinoma, namely, miR9, miR96, miR135b, miR137, miR147, miR182, miR183, miR196b, miR224, and miR503. Of these, miR135b and miR147 were significantly downregulated in colorectal adenoma but upregulated in carcinoma. In addition, we studied the gene expression profile associated with colorectal adenocarcinoma and identified three genes, namely, ZBED3, SLC10A3, and FOXQ1, that were significantly downregulated in colorectal adenoma compared to carcinoma. Interestingly, of all the miRNAs and genes associated with colorectal adenocarcinoma, the myoglobin (MB) gene was identified to be under the direct influence of miR135b, showing an inverse relationship between them in adenoma and carcinoma. Most of the identified miRNAs and associated genes are involved in signaling pathways of cell proliferation, angiogenesis, and metastasis. The present study has identified putative miRNA targets and their associated gene networks which could be used as potential biomarkers of colon adenocarcinoma. Moreover, the association of miR135b and MB gene is very unique and can be considered as a lead candidate for novel cancer therapeutics.

1. Introduction

Colorectal cancer is one of the most common gastrointestinal cancers that shows a rising trend due to the dietary habits and lifestyle modifications. Accumulation of genetic and epigenetic aberrations predisposes the colonic epithelium to undergo gradual transformation with loss of cellular architecture and initiation of a benign adenoma, which subsequently develops into a malignant adenocarcinoma [1]. Successful screening methods have enabled early detection and hence reduction in the mortality rate associated with colorectal adenocarcinoma [2]. In addition to the oncogenes and the tumor suppressor genes involved in cancer initiation and progression, many other small molecules such as the oncoproteins, antisense RNAs, and microRNAs (miRNAs) are also implicated in cancer and its signaling mechanisms [3].

Among the small molecules involved in cancer progression and metastasis, the microRNAs (miRNAs) which are 21–25 nucleotides in length belong to the class of noncoding small RNA molecules that act as posttranslational regulators and are known to exert significant influence on most cancers [46]. Although the miRNAs constitute only 1–3% of the human genome, the fact that about 50% of the miRNA genes are located in the cancer associated loci indicates that these molecules are involved in either cancer progression or inhibition [5, 7]. Many different miRNAs such as let-7, miR-24, miR-143, and miR-192 are involved in direct or indirect regulations of the KRAS or dihydrofolate signaling pathways of colorectal cancer cell proliferation [810]. Additionally, downregulations of miR-143 and miR-195 are reported to target the antiapoptotic Bcl-2 and hence induce apoptosis in colorectal cancer cell lines [11, 12]. As such the miRNAs are considered to hold great potential as diagnostic and prognostic markers of colorectal cancer [13].

Currently, there are about 2019 unique mature human miRNA sequences as revealed by the miRBase 19 (miRNA database of published miRNA sequences and annotation). Given the increasing numbers of miRNAs and the fact that they have diverse expression patterns and regulations ranging from developmental biology to cancer pathology [14], it becomes a practical difficulty to validate each miRNA in order to understand their biological targets. Though high-throughput technologies such as gene chip facilitate genome-wide expression analysis of genes either in normal or diseased states, this leads to generation of enormous data which again pose great difficulty in analysis. As such bioinformatics algorithms based analysis becomes inevitable to select lead candidates and targets which could be then taken up for further validation. Recently, Li et al., 2011 [15], have used partial least square regression analysis approach for predicting miRNA targets in human colon cancer and reported that they were able to detect more miRNA-mRNA targets than a simple correlation based association in colorectal cancer. However, comparisons between numerous studies on miRNA-mRNA associations are necessary for the validation of such technology based predictions before it can be considered as an effective diagnostic/prognostic indicator.

Given the scope of high-throughput technologies and the power of bioinformatics analysis, we have carried out an in-depth in silico analysis of miRNAs associated with colorectal adenoma and carcinoma. Using high-throughput gene expression as well as integrated network and pathway analyses strategies, we have critically dissected the differentially expressed miRNAs and associated gene networks in colorectal adenoma and carcinoma, respectively. We have also identified some of the predictive and therapeutic markers associated with adenoma and carcinoma and their potential to activate the adenoma-carcinoma sequel.

2. Methodology

Five different microarray data sets with genome-wide and miRNA expression associated with colorectal adenoma and carcinoma were used in this study. All data were obtained from recent studies on homosapiens, and the details are provided in Table 1.

StudyPlatformGEO accessionSpeciesSourceDescription Sample size

Galamb et al., 2010 [16]Affymetrix HGU133 Plus 2.0 GSE15960Homo SapiensmRNAColonic epithelial cells normal, adenoma, or colorectal cancer tissues18
Sarver et al., 2009 [17]Illumina Human v1 MicroRNA expression beadchipGSE18392Homo SapiensmiRNAMacrodissected colon tumors and normal colon tissue145
Arndt et al., 2009 [18]Ambion Human_Mouse_Rat mirVANA miRNA Bioarray_1566V1GSE10259Homo SapiensmiRNAColon cancer and normal tissues66
Slattery et al., 2011 [19]Agilent Human miRNA V3.0 MicroarraysNAHomo SapiensmiRNAColon and rectal tumors and normal tissue 100
Schetter et al., 2008 [20]OSU-CCC MicroRNA Microarray Version 2.0 GSE7828Homo SapiensmiRNAColon tumor and adjacent nontumorous tissues168

The above evidence table depicts the authors of the study, high-throughput platform used, data repository accession number, species, source material, and the number of arrays used in each study.

3. Genome-Wide Transcriptomic and miRNA Analysis

Raw CEL files corresponding to gene expression data GSE15960 [16] were transferred to PARTEK Genomics Suite version 6.5 0 (Partek Inc., MO, USA) and normalized using GCRMA with quantile normalization to correct for variances in distribution patterns and GC nucleotide content. Principal component analysis (PCA) was performed on all probes to visualize high dimensional data. PCA was used to demonstrate quality control as well as overall variance in gene expression between the disease states. Analysis of variance (ANOVA) was applied on the whole data set, and differentially expressed gene list was then generated using an FDR (Benjamini Hochberg) of 0.05 with 2-fold change cutoff.

4. Functional and Pathway Analyses

To define biological networks among the differentially regulated genes in adenoma and carcinoma, pathway analyses were performed using Ingenuity Pathways Analysis software (IPA) (Ingenuity Systems, Redwood City, CA, USA). Differentially expressed mRNAs and miRNAs that were specific for colorectal adenoma and carcinoma was imported into IPA. The association analysis between miRNAs and gene signatures from the list of imported molecules were deduced using IPA knowledgebase. Expression values were plotted against the respective miRNAs and genes to identify the expression patterns, and only those miRNAs and genes that were differentially expressed between adenoma and carcinoma were considered for further IPA analysis. The functional analysis of IPA identified the biological functions and/or diseases that were most significantly altered for the differentially expressed gene set. The canonical pathway analysis identified the pathways that were most significantly induced in adenoma and carcinoma of the colon. The significance of the association between the data set and the canonical pathways was calculated by ratio and/or Fisher’s exact test. The genes or gene products are represented as nodes, and the biological relationship between two nodes is represented by a line. Those molecules that are not linked were removed from the IPA analysis.

5. Results

The expression analysis of miRNAs associated with colorectal adenoma and carcinoma in the present study led to the identification of several miRNAs that were differentially expressed in colorectal adenoma (see Table S1A in Supplementary Material available online at and carcinoma (Table S1B). These miRNAs consisted of both tumor suppressors and oncogenes. The following oncomirs, namely, miR-21, miR-20a, miR-224, and miR-18a, were upregulated in colorectal carcinoma, whereas the following tumor suppressors, namely, miR-29a and miR-29c, miR-145, miR-35, and miR-26a, were downregulated. In contrast, only one of the oncomirs, the oncogenic miR-18a, was upregulated, and there were no known tumor suppressors that were downregulated in colorectal adenoma.

Ten unique miRNAs were commonly expressed in both adenoma and carcinoma (Figure 1(a)). Amongst these, both miR-135b and miR-147 showed differential expression patterns, being downregulated in colorectal adenoma and upregulated in carcinoma. The following miRNAs, namely, miR-182, miR-183, miR-196b, miR-224, miR-503, and miR-96, were upregulated while miR-137 and miR-9 were downregulated in both adenoma and carcinoma, respectively. However, both upregulation and downregulation of the individual miRNAs were relatively higher in colorectal carcinoma compared to adenoma (Figure 1(b)).

Among the genes regulated by these 10 commonly expressed miRNAs, the zinc-finger BED domain containing 3 (ZBED3), and solute carrier family 10 (sodium/bile acid cotransporter family), member 3 (SLC10A3) genes showed differential expression patterns, being downregulated in colorectal adenoma and upregulated in carcinoma (Figure 2(a)). In addition, FOXQ1 gene expression was 10-fold higher in colorectal carcinoma compared to colorectal adenoma (Figure 2(b)).

Comparison of 2406 genes in adenoma and 1403 genes in carcinoma revealed unique predictive markers as well as the miRNAs and their regulatory targets associated with adenoma-carcinoma sequel (Figure 3(a)). Screening for the regulatory genes in both adenoma and carcinoma that are controlled by the two differentially expressed miRNAs (miR-135b and miR-147) led to the identification of MiR-33 being uniquely expressed in colon adenoma (Figure 3(A)). In addition, the Myoglobin (MB) gene was commonly expressed in both colorectal adenoma and carcinoma that also showed differential expression pattern being upregulated in colorectal adenoma and downregulated in carcinoma (Figure 4(a)). Furthermore, the various signalling mechanisms/interaction networks that are associated with the MB gene based on mRNA-miRNA integration analysis were identified (Figure 4(b)). These include the tumor suppressors (TP53), the angiogenic factors (VEGFA), cell proliferation, adhesion, and inflammatory molecules (EGF, VACM1, and IFNγ).

The network and pathway analyses led to the identification of the cellular and molecular functions associated with miRNAs in both adenoma and carcinoma. The identified miRNAs were primarily associated with various cellular functions including cell proliferation, cell motility, cell cycle, and cell death. The miRNAs that were specific to cellular proliferation were found to be more associated with colon carcinoma (Table S2A), while those miRNAs associated with cell morphology, cell signaling, and interaction were unique to colon adenoma (Table S2B). In general, most of the miRNAs identified in the current study were associated with diseases and disorders that have been previously reported (Table S2C).

The IPA network analysis identified genes such as insulin 1 (Ins1), miR-375, pyruvate dehydrogenase kinase-1(PDK1), and 3-phosphoinositide dependent protein kinase-1(PDPK1) were more represented in colon adenoma (Table S3A), whereas bruton agammaglobulinemia tyrosine kinase (BTK), CASP8 and FADD-like apoptosis regulator (CFLAR), EGF containing fibulin-like extracellular matrix protein 2 (EFEMP2), interleukin 18 (IL18), and miR-346 were the more represented gene networks in colon carcinoma (Table S3B). As expected, the 5 gene networks identified in colon adenoma and the genes that interact with each network were primarily associated with cancer, gastrointestinal disease, carbohydrate metabolism, growth, and cellular proliferation.

In addition, the miRNA-mRNAs association studies revealed distinct gene regulatory signatures in both adenoma and carcinoma. The following tumor suppressors genes, namely, phosphoinositide-3-kinase regulatory subunit 1-alpha (PIK3R1), nibrin (NBN), and neurofibromin 2 (NF2), were downregulated by miRNAs in adenomas (Table 2). Kruppel-like factor 4 (KLF4), tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) and sterile alpha motif, and leucine zipper containing kinase AZK (ZAK) are some of the tumor suppressors that were downregulated in colon carcinoma. The list of miRNAs associated with these tumor suppressors in colon carcinoma is given in Table 3.

miRNAsmiRNA expressionmiRNA regulated genesGene expression

hsa-miR-182Up Down
hsa-miR-503Up Down
hsa-miR-584Up Down
hsa-miR-32Up Down
hsa-miR-96Up Down

Tumor suppressor, #oncogene, oncomirs, and *mature miRNA sequence from the opposite arm of the precursor.

miRNAsmiRNA expressionmiRNA regulated genesGene expression

hsa-let-7iUpAKAP5, EPHA4, KLF9, and PPP1R12BDown
hsa-miR-107 Up Down
hsa-miR-133bUp Down
hsa-miR-135bUp Down
hsa-miR-141UpFOXA1, NR3C1, and PRKACBDown
hsa-miR-152Up Down
hsa-miR-181aUpAKAP5, KITLG, MARCKS, NR3C1, PLCL2, and PPP1R12BDown
hsa-miR-29a UpAKAP5, Down
hsa-miR-346Up Down
hsa-miR-200c Up , KLF9, LPAR1, MARCKS, NR3C1, PPP1R12B, and PRKACBDown
hsa-miR-34aUpIL6R, KITLGDown
hsa-miR-7Up Down
hsa-miR-25Up Down
hsa-miR-145DownABCC1, ATRX, ETS2, INHBB, MYC#, and SCARB1Up
hsa-miR-26aDownCDK8, COL1A2, INHBB, PMAIP1, PPP1R3D, and STK4Up
hsa-miR-9ΩDownDNAJB1, FOXO3#, INHBB, ITGA6, KSR1, NCOA3, NEDD4, and PPATUp

Tumour suppressor, #oncogene, oncomirs, and *mature miRNA sequence from the opposite arm of the precursor.

6. Discussion

In silico based high-throughput expression analyses are being widely used to decipher the changes at the gene, mRNA, and miRNA levels, and such analyses enable us to understand their molecular interactions and networks in both normal and diseased states. Change in the miRNA expression profile is one of the common features observed in the development of cancer [3, 21]. In the present study, genome-wide transcriptomic and miRNA analysis led to the identification of ten unique mRNAs that were commonly expressed in colorectal adenoma and carcinoma. In contrast to the other miRNAs that were expressed and mostly upregulated in both adenoma and carcinoma, two miRNAs, namely, miR9 and miR137, were found to be downregulated in both colorectal adenoma and carcinoma. Decreased expression of miR-137 which was primarily due to abnormal hypermethylation was identified to be one of the early events in colon carcinogenesis, and transfection of colon cancer cell lines with miR-137 resulted in inhibition of cell proliferation [22]. Similarly, decreased expression of miR-137 was also reported with oral cancer and glioblastoma [23] indicating that miR-137 has tumor suppressor properties.

Two of the ten miRNAs, namely, miRNA135b and miRNA147, were differentially expressed, being downregulated in colorectal adenoma and upregulated in carcinoma. Our findings are in line with earlier studies, where miR-147 was downregulated in colon adenoma [24] and miR-135b was upregulated in colon carcinoma [25]. Similarly, downregulation of miR-135b was found to be associated with the progression of oral carcinoma [23]. Moreover, miR-135 is also reported to target the 39 untranslated regions of adenomatous polyposis coli (APC) gene, a key multifunctional tumor suppressor in sporadic and hereditary colon carcinoma, suppresses its expression [26, 27], and induces downstream Wnt signaling [25]. Moreover, miR-135b has been identified as a novel biomarker for pancreatic ductal adenocarcinoma by global microRNA expression profiling of microdissected tissues [28].

Our study showed that upregulation of miR-147 and miR-135b in colon carcinoma was involved in the specific downregulation of gamma-aminobutyric acid receptor beta-subunit gene (GABRB2). MiR-33 is unique to colon adenoma stage and is responsible for the suppression of GABRB2 gene. GABRB2 which is well known to be involved in transport processes of chloride channel has been previously reported as a colorectal cancer subtype classificatory [29]. GABRB2 was also identified as a discriminatory transcript involved in the CRC-Benign versus CRC-Crohn’s disease [29]. The miR-135b, present in the chromosome position 1q32.1 [24], could also play a role in the downregulation of GABRB2 gene.

ZBED3 gene is a novel axin-binding protein that was shown to be involved in Wnt/beta-catenin signaling modulation [30]. Stage specific expression of both ZBED3 and SLC10A3 was observed in our current study and has the potential to be used as a specific biomarker to differentiate adenoma and carcinoma of the colon [31, 32]. Forkhead box Q1 (FOXQ1) transcription factor has recently been reported to play an important role in the promotion of cancer through the upregulation of several genes that promote tumor growth through angiogenesis, antiapoptotic effects [33], and epithelial-mesenchymal transition (EMT) [34]. One of the reasons for the downregulation of ZBED3 and SLC10A3 could be due to the upregulation of miR-224 and miR-96 in adenoma; however, this needs experimental validation (Figure 2(a)). Probably the mechanism of upregulation of these two genes could either be a mutation or polymorphism in the mRNA coding region that could inhibit the binding of the miRNA to these genes [35]. In the presence of miR-33, miR-135a/miR-135b becomes inactive. MiRNA-miRNA synergistic network is least investigated though it has been postulated to be a key factor associated with complex diseases [36]. Our results indicate a potential involvement of both positive and negative synergetic roles for miRNAs in the progression sequel associated with colon adenoma to carcinoma.

We identified MB gene as the differentially expressed target in colon adenoma and carcinoma under the control of miR-135b. The gene was upregulated in adenoma and downregulated in carcinoma. The expression was correlated with the inverse expression pattern of miR-135b in adenoma and carcinoma. Although MB is expressed chiefly in cardiomyocytes and oxidative skeletal muscle fibres, recent studies identified low level of MB being expressed in various nonmuscle tissues [37]. Interestingly, MB gene has been widely implicated in epithelial cancers and given renewed importance in solid tumors [38, 39]. It was shown in vitro that MB was expressed in hypoxic and oxidative stress conditions associated with epithelial tumors [26]. MB is important in both oxygen transport and free radical scavenging, and its expression in human tumor cells promotes differentiation and inhibits metastasis [27]. Solid epithelial tumors such as colon carcinoma could take advantage of proteins such as MB to cope with hypoxic conditions and to control the metabolism of reactive oxygen and nitrogen species. Furthermore, our study showed for the first time, based on mRNA-miRNA integration analysis, the enhanced expression of MB in adenoma and drastic downregulation in carcinoma of the colon.

The downregulation of Kruppel-like family of transcription factors (KLF4) in colon cancer, and not in adenoma, was associated with the specific upregulation of known oncomirs such as hsa-miR-107 as well as novel oncomirs identified in our study such as hsa-miR-133b, hsa-miR135b, hsa-miR152, hsa-miR-7, and hsa-miR-25. KLF4 functions as a tumor suppressor in several tissues, including the colon, and its specific knockdown induces epithelial-mesenchymal transition which predisposes to the development of a subset of colorectal cancers involving Wnt/beta-catenin signalling mechanisms. [40]. KLF4 also directly inhibits the expression of Bmi1 in colon cancer cells [41].

Phosphatidylinositol 3′-kinase p85alpha regulatory subunit 1 gene (PIK3R1) identified in the current study is also a tumor suppressor, which could potentially be downregulated through miRNA targets and requires validation. Studies on human tumor samples showed increased expression of a coordinately regulated module consisting of PIK3R1 in advanced malignancy [42]. The PI3KR1 gene was also found to be an oncogene in human ovarian and colon tumors [43]. PIK3R1 gene was also one of the genes upregulated by leptin, and this could be one of the causative factors in changing the response of colon epithelial cells possessing an APC mutation but not normal cells. Furthermore, the genes regulating the Wnt/beta-catenin-mediated pathway including PIK3R1 were upregulated by leptin [44], which was consistent with the progression of colon carcinogenesis.

In addition, Nibrin (NBN) was found to be under the regulation of miRNAs and is associated with immortalization of colon carcinoma [45]. NBN was one of the nine genes showing altered expression in both low and high clinical stage colon carcinoma [45]. On the other hand, Neurofibromatosis 2 gene (NF2) is a candidate tumor suppressor gene in chromosome 22.q locus [46], and the colon cancers commonly have allelic losses of chromosome 22q. Consequently, NF2 gene was found to be the target of potential miRNAs in colon carcinoma in our study.

7. Conclusions and Future Directions

In the present study, we have exploited the high-throughput expression analyses strategies to critically delineate the mRNA as well as miRNA expression profiles of adenoma and carcinoma of the colon. Besides, we have identified novel miRNA regulatory networks that regulate the transcription of mRNAs required for the adenoma and carcinoma sequel. It was significant to note that none of the miRNAs and their gene targets identified either in adenoma or carcinoma had overlapped in their expression patterns. This shows that specific miRNAs are expressed in a stage specific manner and regulate their candidate genes in colon adenoma and carcinoma, respectively. These transcriptional networks that regulate genes involved in the molecular functions associated with the differentiation of adenoma into carcinoma provide the predictive markers of colon adenoma-carcinoma sequel and together with RNAa/RNAi strategies to increase the expression of the tumor suppressor genes as well as silencing oncogenes would add tremendously to early detection and management of colon carcinoma.

Conflict of Interests

The authors of the paper, do not have a direct financial relation with the commercial identities mentioned in the paper that might lead to a conflict of interests.

Authors’ Contribution

Kothandaraman Narasimhan and Jayapal Manikandan conceived the study, participated in its design and coordination, and helped to draft the paper. Kalamegam Gauthaman, Peter Natesan Pushparaj, Govindasamy Meenakumari, Adeel Gulzar Ahmed Chaudhary, Adel Abuzenadah, Mamdooh Abdullah Gari, and Mohammed Al Qahtani participated in the design of the study and performed the statistical analysis as well as helping to draft the paper.


The authors wish to acknowledge the Centre for Excellence in Genomic Medicine Research (CEGMR), King Abdul Aziz University, for providing funds for the project (grant title: Identification of circulating nucleic acids as markers for colorectal cancer) as well as for providing space and computing infrastructure to carry out the work. This project was supported by the NSTIP strategic technologies program in the Kingdom of Saudi Arabia, Award no. 11-MED1550-03, and the authors, therefore, acknowledge with thanks STU, KAU, for technical financial support.

Supplementary Materials

Table SIA. miRNAs differentially regulated in colon adenoma tissues. We also describe the biomarker functions associated with each specifc miRNAs which is correlated with their expression. Ω - Tumour suppressor, # - oncogene, †- oncomirs, * mature miRNA sequence from the opposite arm of the precursor.

Table SIB. Summary of miRNAs differentially regulated in colon carcinoma tissues. We also describe the biomarker functions associated with each specifc miRNAs which is correlated with their expression. Ω - Tumour suppressor, # - oncogene, †- oncomirs, * mature miRNA sequence from the opposite arm of the precursor.

Table SIIA. Molecular and cellular function associated with miRNAs involved in colon adenoma tissues.

Table SIIB. Molecular and cellular function associated with miRNAs involved with colon carcinoma tissues.

Table SIIC. Our analysis on miRNAs showed a broader impact of miRNAs in various types of diseases and disorders associated with human beings which is consistent with the nature of action of miRNAs in general. These miRNAs though found associated with colon adenoma and colon carcinoma were found to affect a wide spectrum of diseases as listed below in the table SIIC.

Table SIIIA. Genes and miRNAs most overrepresented in networks associated with colon adenoma. 5 networks were identified to be associated with colon carcinoma. Those genes and miRNAs that were represented 2 or more times were shown in the table.

Table SIIIB. Genes and miRNAs most overrepresented in networks associated with colon carcinoma. 13 networks were identified to be associated with colon carcinoma. Those genes and miRNAs that were represented 10 or more times were shown in the table.

  1. Supplementary Material


  1. W. M. Grady and J. M. Carethers, “Genomic and epigenetic instability in colorectal cancer pathogenesis,” Gastroenterology, vol. 135, no. 4, pp. 1079–1099, 2008. View at: Publisher Site | Google Scholar
  2. C. E. Desch, A. B. Benson, M. R. Somerfield et al., “Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8512–8519, 2005. View at: Google Scholar
  3. W. K. K. Wu, P. T. Y. Law, C. W. Lee et al., “MicroRNA in colorectal cancer: from benchtop to bedside,” Carcinogenesis, vol. 32, no. 3, pp. 247–253, 2011. View at: Publisher Site | Google Scholar
  4. P. N. Pushparaj, J. J. Aarthi, S. D. Kumar, and J. Manikandan, “RNAi and RNAa–the yin and yang of RNAome,” Bioinformation, vol. 2, no. 6, pp. 235–237, 2008. View at: Google Scholar
  5. J. Manikandan, J. J. Aarthi, S. D. Kumar, and P. N. Pushparaj1, “Oncomirs: the potential role of non-coding microRNAs in understanding cancer,” Bioinformation, vol. 2, no. 8, pp. 330–334, 2008. View at: Google Scholar
  6. X. Zhong, G. Coukos, and L. Zhang, “miRNAs in human cancer,” Methods in Molecular Biology, vol. 822, pp. 295–306, 2012. View at: Publisher Site | Google Scholar
  7. B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, “microRNAs as oncogenes and tumor suppressors,” Developmental Biology, vol. 302, no. 1, pp. 1–12, 2007. View at: Publisher Site | Google Scholar
  8. O. Slaby, M. Svoboda, P. Fabian et al., “Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer,” Oncology, vol. 72, no. 5-6, pp. 397–402, 2008. View at: Publisher Site | Google Scholar
  9. Y. Akao, Y. Nakagawa, and T. Naoe, “MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers,” Oncology Reports, vol. 16, no. 4, pp. 845–850, 2006. View at: Google Scholar
  10. J. S. L. Earle, R. Luthra, A. Romans et al., “Association of MicroRNA expression with microsatellite instability status in colorectal adenocarcinoma,” Journal of Molecular Diagnostics, vol. 12, no. 4, pp. 433–440, 2010. View at: Publisher Site | Google Scholar
  11. H. Liu, A. R. Brannon, A. R. Reddy et al., “Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma,” BMC Systems Biology, vol. 4, article 51, 2010. View at: Publisher Site | Google Scholar
  12. P. M. Borralho, B. T. Kren, R. E. Castro, I. B. Moreira Da Silva, C. J. Steer, and C. M. P. Rodrigues, “MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells,” FEBS Journal, vol. 276, no. 22, pp. 6689–6700, 2009. View at: Publisher Site | Google Scholar
  13. H. Cheng, L. Zhang, D. E. Cogdell et al., “Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis,” PLoS ONE, vol. 6, no. 3, Article ID e17745, 2011. View at: Publisher Site | Google Scholar
  14. L. He and G. J. Hannon, “MicroRNAs: small RNAs with a big role in gene regulation,” Nature Reviews Genetics, vol. 5, no. 7, pp. 522–531, 2004. View at: Publisher Site | Google Scholar
  15. X. Li, R. Gill, N. G. Cooper, J. K. Yoo, and S. Datta, “Modeling microRNA-mRNA interactions using PLS regression in human colon cancer,” BMC Medical Genomics, vol. 4, article 44, 2011. View at: Publisher Site | Google Scholar
  16. O. Galamb, S. Spisák, F. Sipos et al., “Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor,” British Journal of Cancer, vol. 102, no. 4, pp. 765–773, 2010. View at: Publisher Site | Google Scholar
  17. A. L. Sarver, A. J. French, P. M. Borralho et al., “Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states,” BMC Cancer, vol. 9, article 401, 2009. View at: Publisher Site | Google Scholar
  18. G. M. Arndt, L. Dossey, L. M. Cullen et al., “Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer,” BMC Cancer, vol. 9, article 374, 2009. View at: Publisher Site | Google Scholar
  19. M. L. Slattery, E. Wolff, M. D. Hoffman, D. F. Pellatt, B. Milash, and R. K. Wolff, “MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype,” Genes Chromosomes and Cancer, vol. 50, no. 3, pp. 196–206, 2011. View at: Publisher Site | Google Scholar
  20. A. J. Schetter, S. Y. Leung, J. J. Sohn et al., “MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma,” Journal of the American Medical Association, vol. 299, no. 4, pp. 425–436, 2008. View at: Publisher Site | Google Scholar
  21. M. Agostini, S. Pucciarelli, F. Calore, C. Bedin, M. Enzo, and D. Nitti, “MiRNAs in colon and rectal cancer: a consensus for their true clinical value,” Clinica Chimica Acta, vol. 411, no. 17-18, pp. 1181–1186, 2010. View at: Publisher Site | Google Scholar
  22. F. Balaguer, A. Link, J. J. Lozano et al., “Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis,” Cancer Research, vol. 70, no. 16, pp. 6609–6618, 2010. View at: Publisher Site | Google Scholar
  23. L. Scapoli, A. Palmieri, L. Lo Muzio et al., “MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 4, pp. 1229–1234, 2010. View at: Google Scholar
  24. A. L. Oberg, A. J. French, A. L. Sarver et al., “MiRNA expression in colon polyps provides evidence for a multihit model of colon cancer,” PLoS ONE, vol. 6, no. 6, Article ID e20465, 2011. View at: Publisher Site | Google Scholar
  25. R. Nagel, C. Le Sage, B. Diosdado et al., “Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer,” Cancer Research, vol. 68, no. 14, pp. 5795–5802, 2008. View at: Publisher Site | Google Scholar
  26. S. E. Flonta, S. Arena, A. Pisacane, P. Michieli, and A. Bardelli, “Expression and functional regulation of myoglobin in epithelial cancers,” American Journal of Pathology, vol. 175, no. 1, pp. 201–206, 2009. View at: Publisher Site | Google Scholar
  27. M. Galluzzo, S. Pennacchietti, S. Rosano, P. M. Comoglio, and P. Michieli, “Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis,” Journal of Clinical Investigation, vol. 119, no. 4, pp. 865–875, 2009. View at: Publisher Site | Google Scholar
  28. J. B. Munding, A. T. Adai, A. Maghnouj et al., “Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma,” International Journal of Cancer, vol. 131, no. 2, pp. E86–E95, 2012. View at: Publisher Site | Google Scholar
  29. O. Galamb, F. Sipos, N. Solymosi et al., “Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 10, pp. 2835–2845, 2008. View at: Publisher Site | Google Scholar
  30. T. Chen, M. Li, Y. Ding et al., “Identification of zinc-finger BED domain-containing 3 (Zbed3) as a novel axin-interacting protein that activates Wnt/β-catenin signaling,” Journal of Biological Chemistry, vol. 284, no. 11, pp. 6683–6689, 2009. View at: Publisher Site | Google Scholar
  31. F. Andre, B. Job, P. Dessen et al., “Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array,” Clinical Cancer Research, vol. 15, no. 2, pp. 441–451, 2009. View at: Publisher Site | Google Scholar
  32. L. Cheng, W. Lu, B. Kulkarni et al., “Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies,” Gynecologic Oncology, vol. 117, no. 2, pp. 159–169, 2010. View at: Publisher Site | Google Scholar
  33. H. Kaneda, T. Arao, K. Tanaka et al., “FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth,” Cancer Research, vol. 70, no. 5, pp. 2053–2063, 2010. View at: Publisher Site | Google Scholar
  34. H. Zhang, F. Meng, G. Liu et al., “Forkhead transcription factor Foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis,” Cancer Research, vol. 71, no. 4, pp. 1292–1301, 2011. View at: Publisher Site | Google Scholar
  35. D. Landi, F. Gemignani, A. Naccarati et al., “Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer,” Carcinogenesis, vol. 29, no. 3, pp. 579–584, 2008. View at: Publisher Site | Google Scholar
  36. J. Xu, C.-X. Li, Y.-S. Li et al., “MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features,” Nucleic Acids Research, vol. 39, no. 3, pp. 825–836, 2011. View at: Publisher Site | Google Scholar
  37. S. B. Kanatous and P. P. A. Mammen, “Regulation of myoglobin expression,” Journal of Experimental Biology, vol. 213, no. 16, pp. 2741–2747, 2010. View at: Publisher Site | Google Scholar
  38. T. A. Gorr, D. Wichmann, C. Pilarsky et al., “Old proteins - new locations: myoglobin, haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells,” Acta Physiologica, vol. 202, no. 3, pp. 563–581, 2011. View at: Publisher Site | Google Scholar
  39. B. K. Zehentner and D. Carter, “Mammaglobin: a candidate diagnostic marker for breast cancer,” Clinical Biochemistry, vol. 37, no. 4, pp. 249–257, 2004. View at: Publisher Site | Google Scholar
  40. J. L. Yori, E. Johnson, G. Zhou, M. K. Jain, and R. A. Keri, “Krüppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression,” Journal of Biological Chemistry, vol. 285, no. 22, pp. 16854–16863, 2010. View at: Publisher Site | Google Scholar
  41. T. Yu, X. Chen, W. Zhang et al., “Regulation of the potential marker for intestinal cells, Bmi1, by β-catenin and the zinc finger protein KLF4: implications for colon cancer,” Journal of Biological Chemistry, vol. 287, no. 6, pp. 3760–3768, 2012. View at: Publisher Site | Google Scholar
  42. S. Kaiser, Y.-K. Park, J. L. Franklin et al., “Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer,” Genome Biology, vol. 8, no. 7, article R131, 2007. View at: Publisher Site | Google Scholar
  43. A. J. Philp, I. G. Campbell, C. Leet et al., “The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors,” Cancer Research, vol. 61, no. 20, pp. 7426–7429, 2001. View at: Google Scholar
  44. J. I. Fenton, J. A. Lavigne, S. N. Perkins et al., “Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotype-dependent fashion,” Molecular Carcinogenesis, vol. 47, no. 1, pp. 9–21, 2008. View at: Publisher Site | Google Scholar
  45. A. Witkowska, J. Gumprecht, J. Glogowska-Ligus et al., “Expression profile of significant immortalization genes in colon cancer,” International Journal of Molecular Medicine, vol. 25, no. 3, pp. 321–329, 2010. View at: Publisher Site | Google Scholar
  46. A. K. Rustgi, L. Xu, D. Pinney et al., “Neurofibromatosis 2 gene in human colorectal cancer,” Cancer Genetics and Cytogenetics, vol. 84, no. 1, pp. 24–26, 1995. View at: Publisher Site | Google Scholar

Copyright © 2014 Kothandaraman Narasimhan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1409 Views | 1327 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.